Multisystem Inflammatory Syndrome in Children (MIS-C)Symptoms, Doctors, Treatments, Advances & More
Multisystem Inflammatory Syndrome in Children (MIS-C) Overview
Learn About Multisystem Inflammatory Syndrome in Children (MIS-C)
Office
Edward Behrens is a Pediatric Rheumatologist practicing medicine in Philadelphia, Pennsylvania. Dr. Behrens is rated as an Elite provider by MediFind in the treatment of Multisystem Inflammatory Syndrome in Children (MIS-C). He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Multisystem Inflammatory Syndrome in Children (MIS-C), Juvenile Idiopathic Arthritis (JIA), Liver Failure, and Arthritis. Dr. Behrens is currently accepting new patients.
Pediatric Rheumatology Program
Lauren Henderson is a Pediatric Rheumatologist practicing medicine in Boston, Massachusetts. Dr. Henderson is rated as an Elite provider by MediFind in the treatment of Multisystem Inflammatory Syndrome in Children (MIS-C). She is also highly rated in 5 other conditions, according to our data. Her clinical expertise encompasses Juvenile Idiopathic Arthritis (JIA), Multisystem Inflammatory Syndrome in Children (MIS-C), Arthritis, and Kawasaki Disease. Dr. Henderson is currently accepting new patients.
Suburban Geriatrics Inc
Robert Pearlstein is a primary care provider, practicing in Geriatrics and Internal Medicine in Plymouth Meeting, Pennsylvania. Dr. Pearlstein is rated as a Distinguished provider by MediFind in the treatment of Multisystem Inflammatory Syndrome in Children (MIS-C). He is also highly rated in 180 other conditions, according to our data. His clinical expertise encompasses Dementia, Alzheimer's Disease, Painful Swallowing, Gastrostomy, and Endoscopy. Dr. Pearlstein is board certified in . Dr. Pearlstein is currently accepting new patients.
Summary: Multisystem inflammatory syndrome in children (MIS-C) is a severe complication associated with SARS-CoV-2 infection that frequently affects the cardiovascular system. Although acute cardiac abnormalities usually resolve, the long-term cardiovascular consequences of MIS-C remain uncertain. Previous follow-up of this cohort 2 years after MIS-C identified signs of subclinical cardiovascular abnormali...